AR and prostate carcinoma: Inhibitors of EZH2: Small molecular weight inhibitors of the EZH2 methylase activity have been developed and many Phase I/II trials are now ongoing to evaluate their efficacy against solid cancers, including castrate-resistant prostate cancer (in combination with an inhibitor of AR signaling), as well as cancers of the hemopoietic system.